NCT00831857已完成不适用
89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Sunitinib or Bevacizumab Plus Interferon; a Pilot Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- The primary endpoint is the change in SUV between baseline 89Zr-bevacizumab PET scan and the scan performed after 2 and 6 weeks of treatment with sunitinib or bevacizumab plus interferon in patients with RCC.
研究概览
简要总结
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with sunitinib or bevacizumab plus interferon in patients with RCC. 89Zr-bevacizumab PET imaging will be regarded a promising biomarker if the target for treatment (VEGF) can be visualised and if uptake changes after institution of treatment.
详细描述
- To explore if 89Zr-bevacizumab PET imaging can differentiate RCC patients with progressive disease from patients with non-progressive disease during treatment with sunitinib or bevacizumab plus interferon.
- To explore relationships between VEGF pathway related biomarkers and 89Zr-bevacizumab PET response.
- To explore effect of 2 weeks off treatment in the sunitinib arm on pharmacodynamic biomarkers and 89Zr-bevacizumab PET response.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
The primary endpoint is the change in SUV between baseline 89Zr-bevacizumab PET scan and the scan performed after 2 and 6 weeks of treatment with sunitinib or bevacizumab plus interferon in patients with RCC.
时间窗: after 2 and 6 weeks
次要结局
- Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progression is defined as the appearance of new disease or an increase of 20% in the sum of the longest diameters of the target lesions.(3 months after treatment)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple MyelomaMultiple MyelomaNCT01859234University Medical Center Groningen20
撤回
1 期
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal CancerMetastatic Colon CancerNCT03764137University of Alabama at Birmingham
已完成
不适用
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine TumorsNeuroendocrine TumorsNCT01338090University Medical Center Groningen14
已完成
不适用
89Zr-bevacizumab PET imaging as predictive biomarker for everolimus efficacy in patients with neuroendocrine tumorshormone producing cancerneuroendocrine tumors10014713NL-OMON32849niversitair Medisch Centrum Groningen14
已完成
不适用
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot studyNL-OMON33835niversitair Medisch Centrum Groningen26